Introduction {#s01}
============

Cardiac arrhythmias, a leading cause of death in the United States, are often precipitated by premature heartbeats ([@bib16]). Such premature electrical activity, dubbed triggered activity, is a hallmark of pathologies stemming from defects in Ca^2+^ cycling proteins. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is one such syndrome, caused by genetic defects in the RYR2 Ca^2+^ release channel and its complex ([@bib27]; [@bib15]). Such dysfunctional RYR2 gating, in the setting of catecholamine stimulation ([@bib3]), permits the RYR2 channels to reopen during diastole. The resulting aberrant Ca^2+^ release can, in turn, activate depolarizing membrane currents and prompt pro-arrhythmic delayed afterdepolarizations (DADs). These form the basis for the bifocal or multifocal aberrant electrical activity that underlies narrow QRS complex CPVT ([@bib6]; [@bib11]). It is important to note that the RYR2 dysfunction by itself, without the aid of catecholamines, is insufficient to induce triggered activity or the resulting ventricular tachycardias (VTs; [@bib11]; [@bib32]). On the other hand, in arrhythmic syndromes such as long QT (LQT), prolongation of the action potential drives triggered activity, specifically early afterdepolarizations (EADs), which in turn lead to reentrant polymorphic VTs marked by a wide QRS complex, dubbed torsades de pointes (TdP; [@bib44], [@bib45]; [@bib41]).

Recent evidence suggests that these two types of triggered arrhythmias share mechanistic similarities ([@bib5]; [@bib36]). Just as with CPVT, various LQT syndromes have been linked to altered RYR2 function ([@bib44]; [@bib14]; [@bib7]; [@bib38]). Furthermore, LQT syndromes can also induce triggered activity via DADs, which result from SR Ca^2+^ release, and the electrogenic Na^+^/Ca^2+^ exchange (NCX; [@bib44]; [@bib4]; [@bib10]; [@bib29]; [@bib28]). However, outside of dysfunctional RYR2 and increased SR Ca^2+^ load, the mechanisms underlying EADs and abnormal Ca^2+^ handling--mediated DADs in LQT are not well understood. Surprisingly, despite the central role of intracellular Ca^2+^ in LQT-promoted arrhythmias, Na^+^ channel blockade has proven to be effective in suppressing triggered activity in these models ([@bib13]; [@bib30]).

Multiple Na^+^ channel isoforms have been identified in the heart. The most abundant, the cardiac-type Na^+^ channels (Na~v~1.5), are primarily distributed on the outer membrane of myocytes and are responsible for electrical excitability ([@bib12]). The other pool of Na^+^ channels, the neuronal Na^+^ channels (nNa~v~s), are localized to membrane invaginations known as transverse tubules ([@bib21], [@bib22]; [@bib48]; [@bib31], [@bib32]; [@bib42]) and modulate excitation--contraction coupling ([@bib19]; [@bib17]; [@bib40]). Although Na~v~1.5 mutations have been linked to LQT syndrome ([@bib47]), the role of noncardiac-type Na~v~ isoforms in LQT syndrome remains unclear. Recently, we demonstrated that physiological Na^+^ influx through nNa~v~, in a setting of RYR2 dysfunction, as evidenced during catecholamine stimulation, can trigger arrhythmias ([@bib31], [@bib32]). Here, we propose that Na^+^ influx through nNa~v~, along with dysfunctional RYR2, and enhanced SR Ca^2+^ load can conspire to prompt arrhythmias in LQT-driven pathologies as well as those resulting directly from Ca^2+^ cycling defects (i.e., CPVT). To this end, we demonstrate a key role for nNa~V~s in triggered activity (EADs and DADs) during pharmacologically induced prolongation in repolarization and/or augmentation of global Na~v~ or L-type Ca^2+^ channel activity. Notably, the modulation of the arrhythmia risk by nNa~v~s occurs independently of changes in action potential duration (APD) and QT interval.

Materials and methods {#s02}
=====================

All animal procedures were approved by The Ohio State University Institutional Animal Care and Use Committee and conformed to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 2011).

Myocyte isolation, confocal Ca^2+^ imaging, Na^+^ current, and action potential recordings {#s03}
------------------------------------------------------------------------------------------

Ventricular myocytes were obtained by enzymatic isolation from 3--11-mo-old cardiac calsequestrin (CASQ2)-null mice (on mixed background; [@bib32]) as well as WT (on C57BL/6 background) mice of both genders. Mice were anaesthetized with isoflurane, and once a deep level of anesthesia was reached, the hearts were rapidly removed and Langendorff perfused as previously described ([@bib31], [@bib32]). Whole-cell patch-clamp recordings of action potentials were performed with an Axopatch 200B amplifier using external solution that contained (in mM) 140 NaCl, 5.4 KCl, 1.8 CaCl~2~, 0.5 MgCl~2~, 10 HEPES, and 5.6 glucose, pH 7.4. Patch pipettes were filled with a solution that contained (in mM) 90 potassium aspartate, 50 KCl, 5 MgATP, 5 NaCl, 1 MgCl~2~, 0.1 Tris GTP, 10 HEPES, and 0.1 EGTA, pH 7.2. Action potentials were evoked by injection of brief stimulus current 1.5--4 pA, 0.5--1 ms. Late and peak sodium currents (I~Na~s) were recorded using internal solution containing (in mM) 10 NaCl, 20 TEACl, 123 CsCl, 1 MgCl~2~, 0.1 Tris GTP, 5 MgATP, 10 HEPES, and 1 EGTA while free Ca^2+^ was maintained at 100 nmol/L with CaCl~2~, pH 7.2. The extracellular bathing solution for late I~Na~ recordings contained (in mM) 140 NaCl, 4 CsCl, 1 CaCl~2~, 2 MgCl~2~, 0.05 CdCl~2~, 10 HEPES, 10 glucose, 0.03 niflumic acid, 0.004 strophanthidin, and 0.2 NiCl~2~. pH was maintained at 7.4 with CsOH. For peak I~Na~ recordings, extracellular bathing solution was altered by reducing NaCl to 10 mM, increasing CsCl to 123 mM, and adding 20 mM TEACl. Whole-cell capacitance and series resistance compensation (≥60%) was applied along with leak subtraction. Signals were filtered with a 10-kHz Bessel filter, and I~Na~ was then normalized to membrane capacitance. Late I~Na~ was estimated by integrating I~Na~ between 50 and 450 ms. Intracellular Ca^2+^ cycling was monitored by either Nikon A1R or Olympus FluoView 1000 laser scanning confocal microscope equipped with 60× 1.4-NA oil objectives. For intact, field-stimulated myocytes exposed to 4-aminopyridine (4AP) and anemone toxin II (ATX-II), we used the cytosolic Ca^2+^-sensitive indicator Fluo-3 AM (Molecular Probes) to assess SR Ca^2+^ load. Cells were electrically stimulated at 2 Hz using extracellular platinum electrodes for at least 10 s, and 20 mM caffeine was rapidly applied. To more accurately assess SR Ca^2+^ load in cardiomyocytes exposed to Bay K 8644 (BayK), we used low-affinity cytosolic Ca^2+^-sensitive indicator Fluo-4FF AM (Molecular Probes). The fluorescent probes were excited with the 488-nm line of an argon laser, and emission was collected at 500--600 nm. Fluorescence was recorded in the linescan mode of the confocal microscope.

For simultaneous whole-cell patch-clamp recordings of action potentials and Ca^2+^ waves, patch pipette solution was supplemented with Fluo-3 pentapotassium (0.03 mM; Molecular Probes). Myocytes were paced at 1 Hz to obtain Ca^2+^ wave frequency. Any aberrant Ca^2+^ release event (i.e., a wave or wavelet) that increased cell-wide fluorescence intensity \>10% of the signal generated by the preceding stimulated Ca^2+^ transient was included in the analysis. The fluorescence emitted was expressed as *F*/*F*~0~, where *F* is the fluorescence at time *t* and *F*~0~ represents the background signal. Recordings were made 1 min after solution change, except for ATX-II, which required a 10-min wash-in to achieve steady state. EAD was defined as transient slowing or reversal of membrane potential during repolarization. DAD was defined as a fluctuation from the resting membrane potential of more than 4 mV. After making the baseline recordings, in the majority of experiments, we induced arrhythmogenic events (4AP + isoproterenol \[ISO\], BayK, or ATX-II), which were then followed by sodium channel blocking interventions. We attempted to alternate the order of sodium channel blockers between experiments. All experiments were performed at room temperature (26°C).

Electrocardiographic recordings {#s04}
-------------------------------

Continuous electrocardiographic (ECG) recordings (PL3504 PowerLab 4/35; ADInstruments) were obtained from mice anesthetized with isoflurane (1--1.5%) as previously described ([@bib31], [@bib32]). Briefly, after baseline recording (5 min), a subset of animals received either intraperitoneal ATX-II (30 µg/kg; Alomone Labs) or BayK (1 mg/kg; Tocris). After 10 min, animals received vehicle, riluzole (15 mg/kg; Sigma), or 4,9-anhydro-tetrodotoxin (4,9-ah-TTX; 750 µg/kg; Focus Biomolecules). After an additional 5--10 min, animals were exposed to an intraperitoneal epinephrine (1.5 mg/kg; Sigma) and caffeine (120 mg/kg; Sigma) challenge, and ECG recording continued for 20 min. Because increased heart rate has been linked to reduced arrhythmia inducibility in CPVT ([@bib9]), and because BayK is a potent positive chronotrope ([@bib35]), animals exposed to BayK were pretreated with ivabradine (3 mg/kg; Sigma) 10 min before BayK exposure. ECG recordings were analyzed using the LabChart 7.3 program (ADInstruments). QT interval was measured before catecholamine challenge from the beginning of the QRS complex to the isoelectric baseline for entirely positive T waves or to the trough of any negative T wave ([@bib49]). Heart rate--corrected QT (QTc) intervals were then obtained using the formula QTc = QT/(RR/100)^1/2^ ([@bib24]). VT was defined as three or more premature ectopies with prolonged QRS interval (≥5 ms relative to the one originating during sinus rhythm) and was categorized as either narrow or wide QRS (≥29 ms).

Immunofluorescent labeling of myocytes {#s05}
--------------------------------------

Isolated ventricular myocytes were prepared for immunofluorescence as described previously ([@bib31], [@bib32]). Briefly, cells were plated on laminin-coated glass coverslips, fixed with 4% paraformaldehyde for 5 min, permeabilized with 0.1% Triton X-100, and washed with PBS. Endogenous immunoglobulin was blocked using a 2% BSA PBS solution for 1 h at room temperature and subsequently incubated with primary antibodies. We immunolabeled for nNa~v~s (Na~v~1.1, 1.3, and 1.6; Alomone) and RYR2 (Pierce Antibodies) overnight at 4°C. After washing, goat secondary antibodies (anti--mouse and anti--rabbit) conjugated to Alexa Fluor 488 or 549 (Life Technologies) were added for 1 h.

Data analysis {#s06}
-------------

Action potential and I~Na~ analysis was performed using pCLAMP9 and pCLAMP10.3 software (Molecular Devices). ECG recordings were analyzed using the LabChart 7.3 program (ADInstruments). Line scanning images of Ca^2+^ were normalized for baseline fluorescence ([@bib31], [@bib32]). Ca^2+^ imaging data were processed using ImageJ (National Institutes of Health) and Origin software. Statistical analysis of the data was performed using a Wilcoxon signed rank and Friedman rank sum test or Kruskal--Wallis one-way ANOVA for paired and unpaired data, respectively. The Conover correction with further adjustment by the Holm family-wide error rate method was applied to adjust for multiple comparisons. Data are presented as median with 25th and 75th percentiles (box) and 10th and 90th percentiles (whiskers). Fisher's exact test was used to test differences in nominal data. P \< 0.05 was considered statistically significant.

Online supplemental material {#s07}
----------------------------

Fig. S1 shows the effect of Na^+^ channel blockade on peak Na^+^ current and action potential. Fig. S2 shows the effect of Na^+^ channel blockade on SR Ca^2+^ load during prolonged repolarization. Fig. S3 shows the effect of APD on triggered activity during prolonged repolarization. Fig. S4 shows the effect of nNa~V~ blockade during concomitant exposure to ATX-II on SR Ca^2+^ load. Fig. S5 shows the effect of nNa~V~ blockade during concomitant exposure to BayK on SR Ca^2+^ load. Table S1 shows the impact of nNa~v~ inhibition on RR and QT interval in ATX-II-- and BayK-treated mice.

Results {#s08}
=======

Blockade of nNa~v~s contributes to the cellular antiarrhythmic effect of Na^+^ channel blockade during prolonged repolarization {#s09}
-------------------------------------------------------------------------------------------------------------------------------

We first investigated the role of Na^+^ channel blockade on triggered arrhythmias induced by prolonged repolarization. Specifically, we used 4AP to inhibit transient outward current (I~to~), the major repolarizing current in mouse heart. Notably, exposure of patch-clamped ventricular cardiomyocytes isolated from WT mice to 4AP (4 mM) and ISO (100 nM) resulted in frequent triggered electrical activity in the form of EADs and DADs ([Fig. 1, a and b](#fig1){ref-type="fig"}, red traces and bars). Here we examined the effect of nonselective, pan-Na^+^ channel block with lidocaine (10 µM; [@bib39]), nNa~v~ inhibition with riluzole (10 µM; [@bib37]) or Na~v~1.6 inhibition with 4,9-ah-TTX (300 nM; [@bib33]). At these concentrations, the agents achieved similar levels of I~Na~ reduction (Fig. S1 a), while having no significant effect on APD measured at 90% (APD~90~) repolarization (Fig. S1 b). Next, we examined the impact of these Na~v~-blocking agents on 4AP-promoted cellular triggered activity. Addition of lidocaine (10 µM) to 4AP-ISO--exposed patch-clamped WT cardiomyocytes did not significantly reduce the frequency of triggered activity, whether EADs or DADs ([Fig. 1, a and b](#fig1){ref-type="fig"}, green traces and bars). On the other hand, 4,9-ah-TTX (300 nM) and riluzole (10 µM) significantly reduced triggered activity in 4AP-ISO--exposed WT cardiomyocytes ([Fig. 1, a and b](#fig1){ref-type="fig"}, blue and purple traces and bars), suggesting that nNa~v~ blockade and not necessarily the extent of total I~Na~ reduction contributes to the antiarrhythmic action of Na~v~ blockers during prolonged repolarization achieved with 4AP. Based on this, lidocaine was not used in the investigation of the role of nNa~v~s in the models of LQT-CPVT overlap phenotypes.

![**Blockade of nNa~v~s contributes to the cellular antiarrhythmic effect of Na^+^ channel blockade during prolonged repolarization.** Aberrant Ca^2+^ release and cellular triggered arrhythmias induced by 4AP and ISO are ameliorated by nNa~v~ inhibition. **(a)** Representative examples of action potentials (top), corresponding linescan images (middle), and Ca^2+^ transients (bottom) recorded in WT ventricular cardiomyocytes paced at 1 Hz (black traces) and subsequently exposed to 4AP (4 mM) and ISO (100 nM; red traces), 4AP-ISO + lidocaine (10 µM, green traces), 4AP-ISO + 4,9-ah-TTX (300 nM, blue traces), or 4AP-ISO + riluzole (Ril; 10 µM, purple traces). Addition of 4AP-ISO resulted in frequent EAD (black asterisks) and DAD (black arrows) that often coincided with aberrant Ca^2+^ release events. **(b)** Summary data of cellular arrhythmia event frequency during a mean recording of 67.2 ± 2.2 s 4AP-ISO significantly increased EADs, DADs, and Ca^2+^ waves, which were reduced by the addition of 4,9-ah-TTX or Ril (P \< 0.001, Kruskal--Wallis rank sum test for EADs, DADs, and Ca^2+^ waves). Lidocaine had no significant effect on cellular arrhythmias. *n* = 14, 11, 9, 9, and 9 cells for control, 4AP-ISO, 4AP-ISO + Lido, 4AP-ISO + 4,9-ah-TTX, and 4AP-ISO + Ril from *n* = 9, 8, 6, 7, and 6 animals, respectively.](JGP_201711909_Fig1){#fig1}

To investigate the effects of Na~v~ blockade on aberrant Ca^2+^ handling, we examined the response of aberrant Ca^2+^ release to various Na~v~ blockers during concomitant exposure to 4AP and ISO. Exposure of WT myocytes to 4AP-ISO induced frequent aberrant Ca^2+^ release events ([Fig. 1, a and b](#fig1){ref-type="fig"}, red traces and bars). Notably, addition of lidocaine (10 µM) had no significant effect on aberrant Ca^2+^ release ([Fig. 1, a and b](#fig1){ref-type="fig"}, green trace and bar), whereas 4,9-ah-TTX (300 µM) significantly reduced aberrant Ca^2+^ release (blue trace and bar). Treatment with riluzole exhibited a trend toward reduction of aberrant Ca^2+^ release relative to myocytes solely exposed to 4AP-ISO and those concomitantly exposed to 4AP-ISO and lidocaine (P = 0.2). In line with these observations, addition of 4,9-ah-TTX and riluzole resulted in a significant increase in SR Ca^2+^ load relative to lidocaine-treated cardiomyocytes (Fig. S2). Collectively, these findings strongly suggest that nNa~v~ blockade, and not necessarily the extent of I~Na~ blockade, contributes to attenuation of aberrant Ca^2+^ handling evidenced during concomitant prolonged repolarization and exposure to β-adrenergic stimulation.

Blockade of nNa~v~s does not abbreviate APD prolongation during slowed repolarization {#s10}
-------------------------------------------------------------------------------------

Slowed repolarization and the corresponding triggered arrhythmias have been attributed to prolongation of cardiac APD ([@bib46]). Specifically, prolonged APD elevates the risk of EADs ([@bib41]), while at the same time promoting aberrant Ca^2+^ handling that underlies DADs ([@bib25]). Therefore, we quantified the effects of 4AP during β-adrenergic stimulation and subsequent Na~v~ inhibition on APD. 4AP+ISO significantly prolonged APD measured at 50% (APD~50~) and APD~90~ repolarization ([Fig. 2 a](#fig2){ref-type="fig"}, red trace and bar) relative to control. As expected, the extent of APD~90~ prolongation correlated with frequency of EADs, but not DADs (Fig. S3). Notably, neither lidocaine (10 µM), 4,9-ah-TTX (300 nM), nor riluzole (10 µM) had a significant effect on APD ([Fig. 2 b](#fig2){ref-type="fig"}, green, blue and purple traces and bars). Despite this, Na~v~ blockade abolished the correlation between APD and EAD frequency (Fig. S3). These findings suggest that although nNa~v~s may contribute to triggered arrhythmias, they do not contribute substantially to APD prolongation evidenced during concomitant prolonged repolarization by 4AP and β-adrenergic stimulation.

![**Na^+^ channel blockade does not substantially alter APD prolongation during slowed repolarization. (a)** Representative example of prolonged action potentials exposed to 4AP-ISO (4 mM and 100 nM, respectively; red trace) and concomitant treatment with lidocaine (Lido, 10 µM; green trace), 4,9-ah-TTX (300 nM; blue trace), or riluzole (Ril; 10 µM; purple trace) recorded in WT ventricular myocytes. Cardiomyocytes were paced at 1 Hz. **(b)** Summary data for APD~50~ and APD~90~ demonstrate increased APDs with 4AP-ISO, 4AP-ISO + Lido, 4AP-ISO + 4,9-ah-TTX, and 4AP-ISO + Ril (P \< 0.001, Kruskal--Wallis rank sum test for APD~50~ and APD~90~; \*, P \< 0.001 vs. control). *n* = 14, 11, 9, 9, and 9 cells for control, 4AP-ISO, 4AP-ISO + Lido, 4AP-ISO + 4,9-ah-TTX, and 4AP-ISO + Ril from *n* = 9, 8, 6, 7, and 6 animals, respectively.](JGP_201711909_Fig2){#fig2}

Inhibition of nNa~v~s ameliorates aberrant Ca^2+^ handling and triggered arrhythmias during augmentation of global Na^+^ influx with ATX-II {#s11}
-------------------------------------------------------------------------------------------------------------------------------------------

We investigated the role of nNa~V~ in triggered arrhythmias induced in a recently established murine model of LQT, where nonselective augmentation of Na^+^ influx with ATX-II caused APD prolongation ([@bib20]). Because LQT has been linked to altered RYR2 function ([@bib14]; [@bib29]; [@bib7]; [@bib28]; [@bib38]), in our study we used a mouse with dysfunctional RYR2 gating caused by an ablation of a key regulatory protein, CASQ2 ([@bib32]). These experiments were conducted in the absence of ISO. As expected, ATX-II (1 nM) elicited a substantial late I~Na~ ([Fig. 3, a and b](#fig3){ref-type="fig"}, red trace and bar). To confirm the nonselective nature of ATX-II, we applied 4,9-ah-TTX and riluzole. Accordingly, only a fraction of ATX-II--induced late I~Na~ was sensitive to selective nNa~v~ blocker 4,9-ah-TTX (300 nM; [Fig. 3, a and b](#fig3){ref-type="fig"}, blue trace and bar). Although blockade with riluzole (10 µM) reduced ATX-II--induced late I~Na~ to a greater extent than 4,9-ah-TTX, it did not abolish this persistent Na^+^ influx induced by ATX-II ([Fig. 3, a and b](#fig3){ref-type="fig"}, purple trace). Functionally, the considerable augmentation of late I~Na~ by 1 nM ATX-II translated into significant prolongation of APD~50~ and APD~90~ ([Fig. 4, a and b](#fig4){ref-type="fig"}, red trace and bar). Notably, both 4,9-ah-TTX (300 nM) and riluzole (10 µM) shortened APD~90~ while having a negligible effect on APD~50~ ([Fig. 4, a and b](#fig4){ref-type="fig"}, blue and purple traces and bars). Analogous to a graded response of ATX-II--induced late I~Na~ to riluzole and 4,9-ah-TTX ([Fig. 3, a and b](#fig3){ref-type="fig"}, blue and purple traces and bars), riluzole abbreviated APD~90~ to a greater extent than 4,9-ah-TTX ([Fig. 4, a and b](#fig4){ref-type="fig"}, purple trace and bar).

![**Impact of nNa~v~ inhibition on ATX-II (1 nM)--induced late Na^+^ current. (a)** Representative traces of late I~Na~ elicited using the protocol shown in the inset. **(b)** Summary data presented as late I~Na~ integral amp-ms/F (AmsF^-1^), which was measured by integrating I~Na~ between 50 and 450 ms. (P \< 0.001, Kruskal--Wallis rank sum test). *n* = 42, 29, 22, and 9 cells from *n* = 20, 12, 8, and 3 animals for control, ATX-II, ATX-II + 4,9-ah-TTX, and ATX-II + riluzole (Ril), respectively. Asterisks denote outliers.](JGP_201711909_Fig3){#fig3}

![**Impact of nNa~v~ inhibition on ATX-II--induced APD prolongation. (a)** Prolongation of action potentials can be detected after addition of ATX-II (1 nM, red traces) and abbreviation after subsequent treatment with either 4,9-ah-TTX (300 nM, blue trace) or riluzole (Ril; 10 µM, purple trace). Cardiomyocytes were paced at 1 Hz. **(b)** Measurement of APD~50~ and APD~90~ demonstrates increased APD with ATX-II treatment, whereas 4,9-ah-TTX (300 nM) and Ril (10 µM) shortened APD~90~ (P \< 0.01, Kruskal--Wallis rank sum test for APD~50~; \*, P \< 0.01 versus control; P \< 0.001, Kruskal--Wallis rank sum test for APD~90~). *n* = 7 unpaired cells from *n* = 4 animals for all experiments.](JGP_201711909_Fig4){#fig4}

Next, we examined the effect of ATX-II--induced APD prolongation on QT interval in vivo. As expected based on cellular data, ATX-II (30 µg/kg) elicited a marked QTc prolongation in CASQ2-null mice ([Fig. 5, a and b](#fig5){ref-type="fig"}; and Table S1, red trace and lines). Pretreatment of mice with 4,9-ah-TTX (750 µg/kg), did not significantly affect QTc interval ([Fig. 5, a and b](#fig5){ref-type="fig"}; and Table S1, blue trace and lines). In contrast, riluzole (15 mg/kg) significantly abbreviated the QTc interval relative to CASQ2-null mice treated with ATX-II alone ([Fig. 5, a and b](#fig5){ref-type="fig"}; and Table S1, purple trace and lines).

![**Impact of nNa~v~ inhibition on ATX-II--induced QT interval prolongation. (a)** Left: Representative examples of ECG traces recorded in CASQ2-null mice exposed to ATX-II (30 µg/kg, red) for 20 min followed by treatment with 4,9-ah-TTX (750 µg/kg, blue) or riluzole (Ril; 15 mg/kg, purple) for 10 min. Vertical dotted lines indicate the trough of the T wave. **(b)** Summary data for mean QTc (P \< 0.001 Kruskal--Wallis rank sum test). *n* = 34, 16, 8, and 10 for baseline, ATX-II, ATX-II + 4,9-ah-TTX, and ATX-II + Ril, respectively.](JGP_201711909_Fig5){#fig5}

Increased late I~Na~ and APD prolongation are both associated with triggered arrhythmias ([@bib1]). Therefore, we quantified the effects of ATX-II (1 nM) and concomitant nNa~v~ inhibition on aberrant Ca^2+^ waves and EAD and DAD frequency. Late I~Na~ augmentation by ATX-II (1 nM) induced frequent aberrant Ca^2+^ waves, which coincided with EADs and DADs ([Fig. 6, a and b](#fig6){ref-type="fig"}, red traces and bars). Despite a large remaining late I~Na~ ([Fig. 3](#fig3){ref-type="fig"}), both 4,9-ah-TTX (300 nM) and riluzole (10 µM) significantly reduced the frequency of aberrant Ca^2+^ waves and triggered activity in the form of EADs or DADs ([Fig. 6, a and b](#fig6){ref-type="fig"}, blue and purple traces and bars). Notably, both 4,9-ah-TTX and riluzole evidenced larger SR Ca^2+^ load relative to control condition (Fig. S4), reflecting Ca^2+^ loading achieved with ATX-II. Furthermore, riluzole evidenced greater Ca^2+^ load relative to 4,9-ah-TTX, suggesting that increased load may parallel greater reduction of cellular arrhythmia burden achieved with riluzole. Collectively, these data suggest that inhibition of nNa~V~s ameliorates triggered arrhythmias during augmentation of global Na^+^ influx with ATX-II.

![**Inhibition of nNa~v~s reduces ATX-II--promoted cellular triggered arrhythmias. (a)** Representative examples of EADs (inset, black asterisks) and DADs (inset, black arrows) recorded in CASQ-null ventricular cardiomyocytes paced at 1 Hz upon exposure to ATX-II (1 nM, red traces), ATX-II + 4,9-ah-TTX (300 nM, blue traces), or ATX-II + riluzole (Ril; 10 µM, purple traces). **(b)** Summary data representing cellular arrhythmia event frequency during 70.5-s recording. ATX-II significantly increased EADs, DADs, and Ca^2+^ waves, which were reduced by the addition of 4,9-ah-TTX or Ril (P \< 0.001 for EADs and Ca^2+^ waves and P \< 0.01 for DADs; Kruskal--Wallis rank sum test). *n* = 7 unpaired cells from *n* = 4 animals for each experiment.](JGP_201711909_Fig6){#fig6}

nNa~v~s and RYR2 colocalize {#s12}
---------------------------

Mitigation of aberrant Ca^2+^ cycling by nNa~v~ blockade suggests close proximity between nNa~v~ and SR Ca^2+^-release machinery. To examine this possibility, we performed confocal immunolocalization experiments in ventricular myocytes isolated from CASQ2-null hearts. Notably, nNa~v~ (Na~v~1.1, Na~v~1.3, and Na~v~1.6) immunofluorescence ([Fig. 7](#fig7){ref-type="fig"}, red) coincided with RYR2 labeling ([Fig. 7](#fig7){ref-type="fig"}, green) and exhibited a periodic pattern consistent with T-tubular localization ([Fig. 7](#fig7){ref-type="fig"}, yellow; [@bib22]; [@bib26]; [@bib31], [@bib32]). These results suggest that nNa~v~s colocalize with RYR2 in the same subcellular regions in the CASQ2-null mouse ventricle, and in part may explain the nNa~v~ contribution to aberrant Ca^2+^ handling.

![**nNa~V~s and RYR2 colocalize to the same discrete subcellular regions. (a--c)** Confocal micrographs of myocytes from CASQ2-null mice with green labeling for RYR2s (top left) and red labeling (top right) for Na~v~1.1 (a), Na~v~1.3 (b), and Na~v~1.6 (c) and the overlay of the two signals (bottom).](JGP_201711909_Fig7){#fig7}

Blockade of nNa~v~s mitigates aberrant Ca^2+^ handling and cellular triggered arrhythmias caused by augmentation of L-type Ca^2+^ channel function {#s13}
--------------------------------------------------------------------------------------------------------------------------------------------------

We investigated the role of nNa~V~ in triggered arrhythmias induced in a model of LQT through augmentation of L-type Ca^2+^ channel activity. Addition of BayK (500 nM) to cardiomyocytes isolated from CASQ2-null mice induced frequent aberrant Ca^2+^ release and the accompanying EADs and DADs ([Fig. 8, a and b](#fig8){ref-type="fig"}, orange traces and bars). Next, we examined the contribution of nNa~V~s to BayK-promoted cellular triggered activity. Addition of 4,9-ah-TTX (300 nM) significantly reduced the frequency of aberrant Ca^2+^ waves and triggered activity ([Fig. 8, a and b](#fig8){ref-type="fig"}, blue traces and bars). Analogous to 4,9-ah-TTX, riluzole (10 µM) significantly reduced aberrant Ca^2+^ handling and triggered activity in BayK-exposed cardiomyocytes ([Fig. 8, a and b](#fig8){ref-type="fig"}, purple traces and bars). Notably, BayK-treated CASQ2-null cardiomyocytes exposed to riluzole evidenced greater SR Ca^2+^ content as assessed by rapid application of caffeine relative to control or those exposed to 4,9-ah-TTX (Fig. S5). Collectively, these data suggest that nNa~v~s contribute to aberrant Ca^2+^ release and triggered activity during augmentation of L-type Ca^2+^ channel activity.

![**Inhibition of nNa~v~ ameliorates BayK-promoted cellular triggered arrhythmias.** Aberrant Ca^2+^ release and cellular triggered arrhythmias induced by BayK are ameliorated by nNa~v~ inhibition. **(a)** Representative examples of action potentials (top), corresponding linescan images (middle), and Ca^2+^ transients (bottom) recorded in CASQ-null ventricular cardiomyocytes paced at 1 Hz (black traces) and subsequently exposed to BayK (500 nM, orange traces), BayK + 4,9-ah-TTX (300 nM, blue traces), or BayK + riluzole (Ril; 10 µM, purple traces). Addition of BayK resulted in frequent EADs (black asterisks), DADs (black arrows), and accompanying aberrant Ca^2+^ release events. **(b)** Summary data of cellular arrhythmia event frequency during a mean recording of 66.4 ± 2.3 s BayK significantly increased EADs, DADs, and arrhythmogenic Ca^2+^ waves, which were reduced by the addition of 4,9-ah-TTX or Ril (P \< 0.001, Kruskal--Wallis rank sum test for EADs, DADs, and Ca^2+^ waves). *n* = 8, 8, 7, and 7 cells from *n* = 4 animals for control, BayK, BayK + 4,9-ah-TTX, and BayK + Ril, respectively.](JGP_201711909_Fig8){#fig8}

Blockade of nNa~v~s does not significantly attenuate action potential and QT interval prolongation during augmentation of L-type Ca^2+^ channel function {#s14}
--------------------------------------------------------------------------------------------------------------------------------------------------------

We quantified the effects of BayK (500 nM) and subsequent nNa~v~ inhibition on APD. Augmentation of L-type Ca^2+^ channel activity with BayK significant prolonged APD~50~ and APD~90~ ([Fig. 9, a and b](#fig9){ref-type="fig"}, orange trace and bar). Notably, both 4,9-ah-TTX (300 nM) and riluzole (10 µM) did not attenuate the effects of BayK on APD ([Fig. 9, a and b](#fig9){ref-type="fig"}, blue and purple traces and bars). In addition, APD prolongation has been demonstrated to underlie LQT interval, which promotes VT ([@bib8]). Here we examined whether APD prolongation associated with augmentation of L-type Ca^2+^ channel activity can give rise to LQT and whether nNa~V~ blockade can reverse this phenotype. Augmentation of L-type Ca^2+^ channel activity with BayK (1 mg/kg) elicited marked QTc prolongation in CASQ2-null mice ([Fig. 10, a and b](#fig10){ref-type="fig"}, orange trace and lines; and Table S1). As expected, pretreatment with neither 4,9-ah-TTX (750 µg/kg) nor riluzole (15 mg/kg) significantly affected QTc interval ([Fig. 10, a and b](#fig10){ref-type="fig"}, blue and purple traces and lines; and Table S1), thereby supporting the notion that nNa~V~ inhibition is insufficient to attenuate prolonged APD and QT interval elicited by BayK.

![**Impact of nNa~v~ inhibition on BayK-induced APD prolongation. (a)** Left: Representative example of prolonged action potentials exposed to BayK (500 nM; orange trace) and subsequent treatment with 4,9-ah-TTX (300 nM; blue trace) or riluzole (Ril; 10 µM; purple trace). Cardiomyocytes were paced at 1 Hz. **(b)** Summary data for APD~50~ and APD~90~ demonstrate increased APDs with BayK, BayK + 4,9-ah-TTX, and BayK + Ril (P \< 0.001 for APD~50~ and P \< 0.01 for APD~90~, Kruskal--Wallis rank sum test; \*, P \< 0.01 vs. control). *n* = 8, 8, 7, and 7 cells from *n* = 4 animals for control, BayK, BayK + 4,9-ah-TTX, and BayK + Ril, respectively.](JGP_201711909_Fig9){#fig9}

![**Impact of nNa~v~ inhibition on BayK-induced QT interval prolongation. (a)** Representative examples of ECG traces recorded in CASQ-null mice treated with ivabradine (3 mg/kg) to prevent BayK-induced rise in intrinsic heart rate for 10 min followed by BayK (1 mg/kg, orange) for either 20 or 10 min and a subsequent treatment with 4,9-ah-TTX (750 µg/kg, blue) or riluzole (Ril; 15 mg/kg, purple) for 10 min. Vertical dotted lines indicate the trough of the T wave. **(b)** Summary data for mean QTc (P \< 0.001, Kruskal--Wallis rank sum test; \*, P \< 0.001 vs. control). *n* = 33, 13, 12, and 8 for control, BayK, BayK + 4,9-ah-TTX, and BayK + Ril, respectively.](JGP_201711909_Fig10){#fig10}

Inhibition of nNa~v~s is sufficient to ameliorate TdP-like VT in vivo {#s15}
---------------------------------------------------------------------

Last, we assessed whether inhibition of nNa~v~ is able to alleviate LQT-promoted VT. Because mice with dysfunctional RYR2 gating caused by an ablation of CASQ2 do not evidence in vivo arrhythmias without catecholamines ([@bib32]), we exposed them to a catecholamine challenge composed of epinephrine (1.5 mg/kg) and caffeine (120 mg/kg). As previously described ([@bib32]), catecholamine challenge induced bidirectional, narrow QRS complex VT with beat-to-beat alternations in the polarity of QRS, characteristic of CPVT, in 20% of animals tested ([Fig. 11, a and b](#fig11){ref-type="fig"}, black trace and bar). None of these animals evidenced the wide QRS complex polymorphic VT often associated with LQT ([@bib20]). On the other hand, BayK induced QT prolongation upon catecholamine challenge, which elicited sustained VTs in \>70% of animals tested ([Fig. 11 b](#fig11){ref-type="fig"}, orange bar). Importantly, a third of these animals evidenced polymorphic VT similar to that shown in [Fig. 11](#fig11){ref-type="fig"} (orange ECG), with a typical short-long-short initiating ventricular cycle leading to a wide (\>29 ms) QRS complex polymorphic VT that resembled human TdP ([Fig. 11, a and c](#fig11){ref-type="fig"}, orange trace and bar). Of note, this TdP-like VT was absent from animals pretreated with nNa~v~s, whether 4,9-ah-TTX (750 µg/kg) or riluzole (15 mg/kg; [Fig. 11, a and c](#fig11){ref-type="fig"}, blue trace and green bars, respectively), whereas this strategy reduced the overall VT incidence by \>50% ([Fig. 11 b](#fig11){ref-type="fig"}, green bar). To further investigate whether inhibition of nNa~v~s can reduce TdP-like VT during global augmentation of Na^+^ influx, we pretreated animals with ATX-II (30 µg/kg; [Fig. 11 a](#fig11){ref-type="fig"}, red trace). Recently, [@bib20] demonstrated that disordered Na~v~ function leading to TdP is readily replicated in mice with ATX-II. This LQT prolongation strategy during catecholamine challange induced VT in \>70% of animals tested ([Fig. 11 b](#fig11){ref-type="fig"}, red bar), and TdP-like VT was observed in more than half of the subjects ([Fig. 11 c](#fig11){ref-type="fig"}, red bar). Consistent with observations in isolated cardiomyocytes, ATX-II--promoted TdP-like VT was sensitive to nNa~v~ inhibition, as pretreatment with 4,9-ah-TTX or riluzole reduced TdP-like VT by half and overall VT by 10-fold ([Fig. 11, b and c](#fig11){ref-type="fig"}, green bars). Collectively, these data highlight that targeting nNa~v~s can be a common antiarrhythmic therapy for LQT-CPVT overlap phenotypes.

![**nNa~v~ inhibition reduces LQT-associated VT. (a)** Representative ECG recordings in CASQ-null mice after catecholamine challenge (black ECG) composed of epinephrine (1.5 mg/kg) and caffeine (120 mg/kg) injected intraperitoneally, which induced a narrow-QRS complex VT exhibiting beat-to-beat alternations in the polarity of QRS. Addition of BayK (1 mg/kg; orange ECG) or ATX-II (30 µg/kg; red ECG) resulted in a typical short-long-short initiating ventricular cycle leading to a wide-QRS complex polymorphic VT that resembled human TdP. A subset of mice 10 min after exposure to BayK or ATX-II and 10 min before catecholamine challenge were pretreated with either 4,9-ah-TTX (750 µg/kg; blue ECGs) or riluzole (Ril; 15 mg/kg). **(b)** VT incidence (%) in CASQ-null mice exposed to catecholamine challenge without (black bars) and with BayK (orange bars) or ATX-II (red bars) during Na^+^ channel blockade with 4,9-ah-TTX or Ril (green bars). Number of mice from independent experiments is specified in the bar graph. VT was defined as three or more premature ectopies. **(c)** TdP-like VT incidence (%) in CASQ-null mice exposed to catecholamine challenge without (black bars) and with BayK (orange bars) or ATX-II (red bars) during Na^+^ channel blockade with 4,9-ah-TTX or Ril (green bars). TdP-like VT was defined as three or more premature wide-QRS ectopies. Significance between the treatment groups was determined with Fisher's exact test.](JGP_201711909_Fig11){#fig11}

Discussion {#s16}
==========

Cardiac arrhythmias are often induced by ectopic triggered activity. Two mechanisms for triggered arrhythmias have been proposed. The first argues that prolonged APD facilitates EAD formation and is thought to underlie reentrant TdP in LQT syndromes ([@bib41]). The second hinges on aberrant Ca^2+^ release through dysfunctional RYR2, which in turn activates depolarizing membrane currents, triggering DADs and repetitive bifocal or multifocal aberrant depolarizations that underlie CPVT ([@bib6]; [@bib2]). Notably, triggered arrhythmias, independent of etiology, have been reported to be sensitive to nNa~v~ blockade ([@bib30], [@bib31], [@bib32]), suggesting that nNa~v~-mediated Na^+^ influx may serve as a common trigger to both types of triggered activity. Here, we demonstrate that nNa~V~s play a role in the generation of aberrant Ca^2+^ release that contributes to EADs and DADs during loss of repolarization reserve (block of repolarizing current with 4AP) and APD prolongation. Furthermore, we demonstrate that, during augmentation of L-type Ca^2+^ or Na^+^ channel function, nNa~v~s contribute to triggered activity and, consequently, to the genesis of both narrow-QRS VT, associated with genetic defects in RYR2, and LQT-associated, wide-QRS, TdP-like VT.

Despite the initial perceived mechanistic divergence between the two types of triggered arrhythmias, emerging evidence suggests a link between pathologies directly driven by Ca^2+^ cycling defects and those arising from QT prolongation. Abnormal RYR2 function ([Fig. 12](#fig12){ref-type="fig"}) and the resultant aberrant Ca^2+^ release have been linked to both types of triggered arrhythmias ([@bib44]; [@bib14]; [@bib29]; [@bib7]; [@bib28]; [@bib38]). However, abnormal RYR2 function by itself is insufficient to induce Ca^2+^ leak and triggered activity in vivo ([@bib11]; [@bib32]). In the case of genetic defects in RYR2, augmentation of Na^+^ entry via nNa~v~ and enhancement of SR Ca^2+^ refill, secondary to β-adrenergic receptor stimulation by catecholamines, are necessary contributors to arrhythmogenesis ([Fig. 12](#fig12){ref-type="fig"}; [@bib32]). Accordingly, in the absence of catecholamines, triggered activity was infrequent in cardiomyocytes isolated from hearts with compromised RYR2 function caused by ablation of CASQ2 ([Figs. 6](#fig6){ref-type="fig"} and [8](#fig8){ref-type="fig"}, black traces). On the other hand, pharmacologically induced LQT by either augmentation of L-type Ca^2+^ channels with BayK ([@bib23]) or augmentation of Na^+^ channels with ATX-II ([@bib43]) has been linked to activation Ca^2+^/CaM-dependent protein kinase II, which in turn renders RYR2 dysfunctional ([Fig. 12](#fig12){ref-type="fig"}). Against this backdrop of altered RYR2 function and increased intracellular Ca^2+^ loading, a disorder marked by prolonged APD and LQT can facilitate aberrant Ca^2+^ release and triggered activity ([Figs. 1](#fig1){ref-type="fig"}, [6](#fig6){ref-type="fig"}, and [8](#fig8){ref-type="fig"}, red, orange, and red traces, respectively). Notably, despite minor effects on pharmacologically elicited APD and QT prolongation ([Figs. 2](#fig2){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [9](#fig9){ref-type="fig"}, red, orange, and red traces, respectively), inhibition of nNa~v~s effectively suppressed aberrant Ca^2+^ release and the accompanying triggered activity. These data are consistent with nNa~v~s contributing to arrhythmogenesis associated with LQT and LQT-CPVT overlap phenotypes ([Fig. 12](#fig12){ref-type="fig"}). Furthermore, overall modulation of Na^+^ current with lidocaine ([Figs. 1](#fig1){ref-type="fig"} and S1) or ATX-II ([Fig. 6](#fig6){ref-type="fig"}), did not completely account for modulation of cellular arrhythmias. It is important to note here that the ATX-II--treated cardiomyocytes evidenced a greater degree of APD prolongation accompanied with a greater EAD burden relative to BayK-treated myocytes, which exhibited more DADs. Given that treatment with either 4,9-ah-TTX or riluzole during exposure to ATX-II increased SR Ca^2+^ load (Fig. S4), this difference may reflect greater intracellular Ca^2+^ loading with ATX-II.

![**Hypothetical scheme for arrhythmogenic factors that are common to both narrow- and wide-QRS VT.** Na^+^ influx through nNa~v~s may facilitate aberrant Ca^2+^ release, which in the setting of RYR2 dysfunction and increased SR Ca^2+^ load can help initiate VT in vivo. Depending on the etiology of the RYR2 dysfunction, whether genetic or acquired secondary to prolonged QT interval, the resulting VT will manifest as either narrow-QRS bidirectional VT or wide-QRS TdP-like VT, respectively. Notably, inhibition of nNa~v~s reduces arrhythmia burden associated with both types of VTs (blue inhibitor marker).](JGP_201711909_Fig12){#fig12}

What differentiates CPVT and LQT-promoted VTs in our model? Consistent with previous results ([@bib15]; [@bib32]), catecholamine challenge induced narrow-QRS complex polymorphic VT, often with QRS polarity alternating beat to beat. This reflects a bifocal or multifocal nature of type of arrhythmias, which stems from Ca^2+^-mediated triggered activity at multiple myocardial sites ([@bib6]). On the other hand, in LQT induced by augmentation of L-type Ca^2+^ channel or Na~v~ activity, catecholamine challenge often resulted in wide-QRS polymorphic VTs that resembled human TdP ([@bib20]). Importantly, nNa~v~ blockade not only abolished these wide-QRS complex VTs, but also reduced the overall VT incidence during combined CPVT and LQT ([Fig. 11 c](#fig11){ref-type="fig"}). Thus, our results suggest that nNa~v~s may be an integral part of the arrhythmogenic trigger in both CPVT and LQT.

How do nNa~V~s contribute to triggered activity? It is well established that nNa~V~s are localized within transverse tubules and along the cell periphery in both WT ([@bib21], [@bib22]; [@bib18]; [@bib26]; [@bib48]) and CPVT ([@bib31], [@bib32]) mice. We recently demonstrated that nNa~V~s, along with NCX and RYR2, are organized into nanodomains along the transverse tubule, providing a structural basis for the functional interplay between cardiac Na^+^ and Ca^2+^ handling ([@bib32]). Therefore, the results from the present study in WT and CASQ2-null cardiomyocytes suggest that the impact of a specific Na~V~ isoform on arrhythmogenesis may depend on its localization relative to Ca^2+^ cycling proteins ([Fig. 7](#fig7){ref-type="fig"}).

Viewed in this structural context, Na^+^ influx via nNa~v~ may occur preferentially near Ca^2+^-cycling proteins (RYR2 and NCX), enhancing NCX-dependent local Ca^2+^ accumulation in the space between the sarcolemma and the RYR2. This nanodomain Ca^2+^ accumulation may prompt Ca^2+^ release via RYR2, resulting in arrhythmogenic triggered activity ([@bib31], [@bib32]; [@bib42]). The evidence that the antiarrhythmic effects of nNa~V~ inhibition result from prevention of aberrant Ca^2+^ release is compelling; however, possible direct effects on the triggered activity threshold should also be considered (Fig. S1). Regardless, our results provide impetus for future work correlating the nanoscale structural organization of specific nNa~V~ isoforms relative to Ca^2+^ cycling proteins with their functional roles in health and disease.

Our results suggest that nNa~v~s contribute to the substrate for LQT-associated fatal polymorphic VT. Further, our results suggest that this is based on modulation of Ca^2+^ cycling by nNa~V~s rather than via global APD and QT prolongation, the classic substrates for reentrant VTs. However, nNa~v~s may contribute to regional heterogeneities in late I~Na~ ([@bib34]) and, consequently, heterogeneous APD prolongation, in turn precipitating reentrant arrhythmias such as TdP ([@bib8]). This intriguing hypothesis merits further investigation. In summary, we demonstrate the antiarrhythmic impact of nNa~v~ inhibition in LQT and CPVT-LQT overlap phenotypes and provide a basis for a mechanistically driven antiarrhythmic strategy using nNa~V~-selective inhibitors.
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